With box warnings

Without box warnings

Branded

Generic

4 results

cabometyx
(cabozantinib)
Exelixis, Inc.
Usage: CABOMETYX is indicated for advanced renal cell carcinoma (RCC), both as a monotherapy and in combination with nivolumab. It is also used for hepatocellular carcinoma (HCC) after sorafenib treatment and for locally advanced or metastatic differentiated thyroid cancer (DTC) in patients 12 and older who are radioactive iodine-refractory.
lenvima
(Lenvatinib)
Eisai Inc.
Usage: LENVIMA is indicated for treating adult patients with radioactive iodine-refractory differentiated thyroid cancer, advanced renal cell carcinoma (in combination with pembrolizumab or everolimus), unresectable hepatocellular carcinoma, and advanced endometrial carcinoma (with pembrolizumab) not amenable to curative surgery or radiation.
sorafenib
(sorafenib)
TWi Pharmaceuticals USA, Inc.
Usage: Sorafenib tablets are indicated for unresectable hepatocellular carcinoma (HCC) and for locally recurrent or metastatic, progressive differentiated thyroid carcinoma (DTC) that is refractory to radioactive iodine treatment.
sorafenib
(sorafenib)
Yabao Pharmaceutical Co., Ltd. Beijing
Usage: Sorafenib tablets are indicated for patients with unresectable hepatocellular carcinoma (HCC) and those with locally recurrent or metastatic, progressive differentiated thyroid carcinoma (DTC) that is refractory to radioactive iodine treatment.

Medications for Differentiated Thyroid Gland Carcinoma

cabometyx